[go: up one dir, main page]

MX2013012281A - Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. - Google Patents

Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.

Info

Publication number
MX2013012281A
MX2013012281A MX2013012281A MX2013012281A MX2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A MX 2013012281 A MX2013012281 A MX 2013012281A
Authority
MX
Mexico
Prior art keywords
treatment
degenerative
diseases
inflammatory diseases
novel compound
Prior art date
Application number
MX2013012281A
Other languages
English (en)
Other versions
MX355653B (es
Inventor
Christel Jeanne Marie Menet
Alastair James Hodges
Huw David Vater
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2013012281A publication Critical patent/MX2013012281A/es
Publication of MX355653B publication Critical patent/MX355653B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan pirrazolopiridinas novedosas de acuerdo con la fórmula I, capaces de inhibir JAK, estos compuestos se pueden preparar como una composición farmacéutica y pueden ser utilizados para la profilaxis y tratamiento de una diversidad de condiciones en mamíferos incluyendo humanos, que incluyen, a modo de ejemplo no limitante, alergias, condiciones inflamatorias, enfermedades autoinmunes, enfermedades proliferativas, rechazo de transplantes, enfermedades que involucran deterioro de recambio del cartílago, malformaciones congénitas del cartílago y/o enfermedades asociadas con hipersecreción de IL6 o interferones.
MX2013012281A 2011-04-28 2012-04-26 Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. MX355653B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479956P 2011-04-28 2011-04-28
PCT/EP2012/057654 WO2012146659A1 (en) 2011-04-28 2012-04-26 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2013012281A true MX2013012281A (es) 2013-11-21
MX355653B MX355653B (es) 2018-04-26

Family

ID=46017860

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013012282A MX360697B (es) 2011-04-28 2012-04-26 Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2013012281A MX355653B (es) 2011-04-28 2012-04-26 Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013012282A MX360697B (es) 2011-04-28 2012-04-26 Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.

Country Status (17)

Country Link
US (5) US8975406B2 (es)
EP (2) EP2702059B1 (es)
JP (2) JP5947372B2 (es)
KR (1) KR101934707B1 (es)
CN (2) CN103492385B (es)
AR (1) AR086042A1 (es)
AU (2) AU2012247482B2 (es)
BR (1) BR112013027338A2 (es)
CA (2) CA2833942A1 (es)
EA (1) EA024743B1 (es)
IL (1) IL228786A (es)
MX (2) MX360697B (es)
SG (1) SG194508A1 (es)
TW (1) TWI536990B (es)
UY (1) UY34037A (es)
WO (2) WO2012146657A1 (es)
ZA (1) ZA201307793B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
MX2015015150A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR101690760B1 (ko) * 2014-11-05 2016-12-30 조길래 피부자극완화, 탈모방지 및 발모촉진 효과를 나타내는 카페오일펜타펩타이드 및 이를 함유하는 탈모방지 및 발모촉진용 화장료 조성물
TW201705961A (zh) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DE102015215820A1 (de) * 2015-08-19 2017-02-23 Siemens Healthcare Gmbh Steuern eines medizintechnischen Geräts
JP6978098B2 (ja) * 2016-07-26 2021-12-08 スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JP6697631B2 (ja) * 2017-03-09 2020-05-20 富士フイルム株式会社 音響レンズ用樹脂材料、音響レンズ、音響波プローブ、音響波測定装置、超音波診断装置、光音響波測定装置および超音波内視鏡
EA037208B1 (ru) * 2017-09-29 2021-02-19 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA035568B1 (ru) * 2017-09-29 2020-07-08 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
TWI783057B (zh) 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
KR20210070286A (ko) * 2018-09-30 2021-06-14 베이징 즈지엔진루이 셩우이야오 커지 요우시엔공스 치환된 피라졸 융합고리계 유도체 및 이의 제조 방법과 응용
US12209085B2 (en) 2018-12-07 2025-01-28 Sunshine Lake Pharma Co., Ltd. RET inhibitors, pharmaceutical compositions and uses thereof
US12312348B2 (en) 2018-12-07 2025-05-27 Sunshine Lake Pharma Co., Ltd. RET inhibitors, pharmaceutical compositions and uses thereof
WO2021213476A1 (zh) * 2020-04-22 2021-10-28 深圳晶泰科技有限公司 一种吡唑并[1,5-a]吡啶类衍生物及其制备方法，组合物以及用途
CN113713083A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗脱发的药物组合
CN116056577A (zh) 2020-09-01 2023-05-02 先正达农作物保护股份公司 具有含硫取代基的杀有害生物活性的杂环衍生物
AU2021347913A1 (en) 2020-09-28 2023-05-18 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
EP4284801A4 (en) * 2021-02-01 2025-04-23 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
CN117836301A (zh) 2021-08-10 2024-04-05 先正达农作物保护股份公司 作为杀有害生物剂的2,2-二氟-5h-[1,3]间二氧杂环戊烯并[4,5-f]异吲哚-7-酮衍生物
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
UY40202A (es) 2022-04-01 2023-10-31 Syngenta Crop Prot Ag Derivados de pirazolopiridina activos como pesticidas con sustituyentes que contienen azufre
CN120584105A (zh) 2023-01-23 2025-09-02 先正达农作物保护股份公司 具有含硫取代基的杀有害生物活性的杂环衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
SG174086A1 (en) * 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica

Also Published As

Publication number Publication date
AU2012247484B2 (en) 2015-02-19
JP5947372B2 (ja) 2016-07-06
AU2012247482A1 (en) 2013-03-28
US20150031706A1 (en) 2015-01-29
US8802682B2 (en) 2014-08-12
US9241931B2 (en) 2016-01-26
TWI536990B (zh) 2016-06-11
SG194508A1 (en) 2013-12-30
US9987272B2 (en) 2018-06-05
EP2702059A1 (en) 2014-03-05
KR101934707B1 (ko) 2019-01-03
WO2012146657A1 (en) 2012-11-01
HK1195311A1 (zh) 2014-11-07
ZA201307793B (en) 2015-04-29
IL228786A0 (en) 2013-12-31
TW201247202A (en) 2012-12-01
KR20140025430A (ko) 2014-03-04
US20180078547A1 (en) 2018-03-22
AR086042A1 (es) 2013-11-13
CN103492386B (zh) 2016-03-09
US20160213666A1 (en) 2016-07-28
US8975406B2 (en) 2015-03-10
EA024743B1 (ru) 2016-10-31
HK1195312A1 (zh) 2014-11-07
UY34037A (es) 2012-11-30
JP2014512405A (ja) 2014-05-22
CN103492385B (zh) 2016-05-11
CA2833942A1 (en) 2012-11-01
WO2012146659A1 (en) 2012-11-01
AU2012247482B2 (en) 2015-03-05
MX360697B (es) 2018-11-14
US20140051677A1 (en) 2014-02-20
JP2014512404A (ja) 2014-05-22
MX2013012282A (es) 2013-11-21
JP5947371B2 (ja) 2016-07-06
CA2833963C (en) 2019-09-17
CN103492385A (zh) 2014-01-01
CA2833963A1 (en) 2012-11-01
IL228786A (en) 2017-04-30
NZ617528A (en) 2015-09-25
EP2702059B1 (en) 2015-08-19
AU2012247484A1 (en) 2013-03-28
US20120277247A1 (en) 2012-11-01
BR112013027338A2 (pt) 2017-08-08
EP2702058B1 (en) 2015-08-19
EA201391584A1 (ru) 2014-04-30
MX355653B (es) 2018-04-26
EP2702058A1 (en) 2014-03-05
CN103492386A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
JO3030B1 (ar) مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
NZ722403A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CR20120016A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MD20150091A2 (ro) Compuşi antivirali
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
PH12013501437A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
HK1201067A1 (en) Sialic acid analogs
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань
NZ803938A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders.

Legal Events

Date Code Title Description
FG Grant or registration